Answers are grounded in this paper and cite their sources.
Background This paper describes a case of necrobiosis lipoidica (NL) which was successfully treated with dupilumab. NL can be a difficult and chronic disease, often with limited treatment options. Dupilumab is a biologic typically used for atopic dermatitis, but given its novel pathway, it has been used in a number of other conditions. Case Presentation We describe a patient with inflammation on her legs, which was biopsied and consistent with NL. Treatments, including topical steroids, were started, but there was no improvement, therefore, dupilumab was discussed. She agreed with the treatment and dupilumab injections, and she reported a decrease in redness and improvement in her NL. Conclusion With this report, hopefully, there will be another option for the treatment of NL and different and novel uses for dupilumab.
No takes yet. Share an insight, caveat, or question.
Monaco et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: